产品
编 号：F300145
分子式：C18H26N2O4S
分子量：366.48
分子式：C18H26N2O4S
分子量：366.48
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 26944-48-9
产品详情
生物活性：
Glibornuride is a blocker of ATP-sensitive K+ channels (KATP channel) with a pKi of 5.75. Antidiabetic agent.
体内研究：
给予 Glibornuride (5 mg/kg；每天灌胃，持续 28 天) 28 天导致瑞士白化大鼠糖尿病组体重增加。 Glibornuride 28 天降低糖尿病大鼠血尿酸水平。 Glibornuride 28 天不显著增加糖尿病大鼠肝脏脂质过氧化水平。Animal Model:6-6.5-month-old male Swiss Albino rats, weighing 150-200 g
Dosage:5 mg/kg
Administration:Given by gavage, daily for 28 days
Result:Administration for 28 days caused an increase in body weights in the diabetic groups. Treatment for 28 days decreased the serum uric acid levels in diabetic rats.
Glibornuride is a blocker of ATP-sensitive K+ channels (KATP channel) with a pKi of 5.75. Antidiabetic agent.
体内研究：
给予 Glibornuride (5 mg/kg；每天灌胃，持续 28 天) 28 天导致瑞士白化大鼠糖尿病组体重增加。 Glibornuride 28 天降低糖尿病大鼠血尿酸水平。 Glibornuride 28 天不显著增加糖尿病大鼠肝脏脂质过氧化水平。Animal Model:6-6.5-month-old male Swiss Albino rats, weighing 150-200 g
Dosage:5 mg/kg
Administration:Given by gavage, daily for 28 days
Result:Administration for 28 days caused an increase in body weights in the diabetic groups. Treatment for 28 days decreased the serum uric acid levels in diabetic rats.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备